慢性丙型肝炎治愈后肠道菌群改善仅见于无肝硬化患者
研究前瞻性分析直接抗病毒药物(DAA)治疗获持续病毒学应答(SVR)的慢性丙型肝炎患者肠道菌群变化。治疗组65例、对照组33例,仅纳入获SVR者。α多样性从基线至SVR24/48数值增加但未达显著(2.784±0.248 vs. 2.846±0.224;P=0.057),分层后仅无肝硬化患者多样性显著增加且菌群结构改变,肝硬化患者及对照组无显著差异。
要点
- 慢性丙肝患者获SVR24/48后肠道菌群α多样性数值增加但未达统计学显著。
- 菌群多样性显著增加及群落结构改变仅见于无肝硬化患者。
- 肝硬化患者即使获SVR,肠道菌群亦无显著改善,提示肝纤维化程度影响菌群恢复。
核心结论
- 慢性HCV患者获SVR24/48与肠道菌群变化相关,但该变化仅见于无肝硬化患者。
- 肠道微生物群落结构动态取决于纤维化阶段,提示肝脏重塑对肠道菌群有重要作用。
研究设计与样本
- 前瞻性研究,对慢性丙型肝炎患者粪便样本行16S rRNA基因V1-V2区域扩增子测序。
- 治疗组接受DAA(n=65),对照组未给DAA(n=33),仅纳入获SVR的患者。
主要发现
- α多样性从基线至SVR24/48数值增加但未达显著(2.784±0.248 vs. 2.846±0.224;P=0.057)。
- 分层分析显示,仅无肝硬化患者α多样性显著增加。
- 获SVR引起的微生物群落结构差异仅见于无肝硬化患者。
- 肝硬化患者及对照组未见显著差异。
临床怎么用
- 对慢性丙肝患者评估肠道菌群改善时,应结合肝纤维化/肝硬化状态分层解读。
- 肝硬化患者获SVR后肠道菌群未必显著改善,提示需关注肝纤维化程度对菌群恢复的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: It is well accepted that liver diseases and their outcomes are associated with intestinal microbiota, but causality is difficult to establish. The intestinal microbiota are altered in patients with hepatitis C. As chronic HCV infection can now be cured in almost all patients, it is an ideal model to study the influence of liver disease on the microbiota. APPROACH AND RESULTS: We aimed to prospectively analyze the changes in the gut microbiome in patients who received direct-acting antivirals (DAA) and achieved sustained virological response (SVR). Amplicon sequencing of the V1-V2 region in the 16S ribosomal RNA gene was performed in stool samples of patients with chronic hepatitis C. Patients in the treatment group received DAA (n = 65), whereas in the control group, no DAA were given (n = 33). Only patients achieving SVR were included. The alpha diversity increased numerically but not significantly from baseline to SVR at week 24 or 48 (SVR24/48; 2.784 ± 0.248 vs. 2.846 ± 0.224; P = 0.057). When stratifying for the presence of liver cirrhosis, a significant increase in diversity was only seen in patients without cirrhosis. Differences in the microbial community structure induced by the achievement of SVR were only observed in patients without liver cirrhosis. In patients with liver cirrhosis and in the control group, no significant differences were observed. CONCLUSIONS: In conclusion, the achievement of SVR24/48 in patients with chronic HCV was associated with changes in the intestinal microbiota. However, these changes were only seen in patients without liver cirrhosis. A major role of liver remodeling on the intestinal microbiota is indicated by the dynamics of the intestinal microbial community structure depending on the stage of fibrosis in patients resolving chronic hepatitis C.
引用
- Wellhöner F, Döscher N, Woelfl F, et al. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology. 2021. PMID: 33411981. doi:10.1002/hep.31700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。